13F Holdings
中文EN

NDRA ENDRA Life Sciences Inc.

Electromedical & Electrotherapeutic Apparatus · Nasdaq · SEC CIK 1681682 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY27.0%
TTM EPS YoY-126.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-217.7%
ROA-134.7%
ROIC (approx.)-360.8%
Asset turnover—

Leverage & solvency

Liabilities / assets22.6%
Debt / equity0.00x
Current ratio7.95x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.93x
Accruals ratio-10.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense$1.85M$3.19M$5.00M$6.55M$5.48M
SG&A expense$3.72M$7.06M$4.70M$5.17M$4.94M
Operating income-$5.76M-$10.82M-$10.52M-$13.16M-$11.50M
Pretax income-$7.03M-$11.51M-$10.06M-$13.18M-$11.55M
Income tax—$0$0$0$0
Net income-$7.03M-$11.51M-$10.06M-$13.18M-$11.23M
EBITDA-$5.72M-$10.77M-$10.40M-$13.06M-$11.38M
EPS (basic)-8.93-56.94—-4.56-5.55
EPS (diluted)-8.93-56.94-2,766.85——
Weighted avg. shares (diluted)787,020202,1063,636——
Balance sheet
Cash & equivalents$762,365$3.23M$2.83M$4.89M$9.46M
Inventory$0$0$2.62M$2.64M$1.28M
Current assets$967,969$3.43M$3.03M$5.38M$12.09M
PP&E, net$42,516$69,281$111,782$235,655$131,130
Total assets$3.85M$4.45M$6.75M$9.27M$12.87M
Current liabilities$750,956$605,230$903,095$1.70M$1.54M
Short-term debt—$0$28,484$28,484—
Long-term debt—$0$0$0$546,631
Total debt—$0$28,484$28,484$546,631
Total liabilities$1.59M$1.89M$1.10M$2.07M$2.09M
Shareholders' equity$2.26M$2.56M$5.66M$7.20M$10.78M
Net debt—-$3.23M-$2.81M-$4.86M-$8.91M
Shares outstanding1.18M536,9085,9373.17M2.13M
Cash flow statement
Operating cash flow-$5.18M-$7.40M-$9.55M-$12.77M-$11.12M
Capital expenditure$17,280$16,000$33,884$202,577$45,000
Free cash flow-$5.20M-$7.42M-$9.58M-$12.97M-$11.17M
Investing cash flow-$3.02M-$12,796-$24,721-$202,577-$45,000
Financing cash flow$5.73M$7.81M$7.52M$8.40M$13.40M
Depreciation & amortization$44,045$46,489$123,726$96,661$116,238
Stock-based compensation$329,409$571,924$996,430$1.20M$1.44M

Free plan shows the latest 5 periods; Pro shows all 10 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.